Fig. 4From: Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and BelgiumOverall and by product treatment discontinuation – stable PP3M patients vs. stable PP1M patientsBack to article page